All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your PsOPsA Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

AAD 2024: Highlights from the IPC report

May 2, 2024
Learning objective: After reading this article, learners will be able to cite updates from the American Academy of Dermatology Annual Meeting 2024.

Bookmark this article

The American Academy of Dermatology (AAD) Annual Meeting 2024 was held in San Diego, U.S., from March 8–12.1 AAD is one of the largest dermatology conferences in the world, with over 1,000 speakers and 300 sessions.1

The International Psoriasis Council (IPC) has provided a report that includes summaries of all 36 talks on psoriasis topics at AAD, and the IPC symposium, which focused on the comprehensive care of psoriasis.1 The IPC is a community of researchers and physicians who work to improve the lives of individuals living with psoriasis.1 Here, we provide a short summary of information included in the report. 

Coverage of psoriatic disease1 

Key topics covered at AAD included: 

  • Biomarkers in psoriasis 

  • Evolving treatment landscapes and pipeline therapies 

  • Management of nail psoriasis 

  • Interleukin inhibitors for psoriasis and psoriatic arthritis 

  • Biosimilars 

  • Impact of comorbidities in treatment selection 

  • Early treatment 

  • Psoriasis management in women 

Late breaking abstracts1 

Topics in the late-breaking abstracts included: 

  • 52-week results from the phase II KNOCKOUT trial (risankizumab) 

  • Light treatment effectiveness (LITE) study 

  • Phase II STRIDE study (ESK-001) 

  • Phase IIb FRONTIER 2 study (JNJ-77242113) 

  • 16-week results from a phase III palmoplantar pustulosis trial (apremilast) 

  • 4-year pooled analysis from BE BRIGHT (bimekizumab) 

  • Reducing CD8+ memory T cells in generalized pustular psoriasis (guselkumab) 

For a comprehensive understanding of the sessions, the complete report can be found on the IPC website. 

  1. Galimany L. Focus on psoriasis: A report from the 2024 American Academy of Dermatology (AAD) Annual Meeting. International Psoriasis Council. Published April 12, 2024. Accessed April 29, 2024. 


Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox